Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$33.14 USD
+0.71 (2.19%)
Updated May 31, 2024 04:00 PM ET
After-Market: $33.13 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Brokerage Reports
0 items in cart
Collegium Pharmaceutical, Inc. [COLL]
Reports for Purchase
Showing records 61 - 80 ( 91 total )
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
1Q19 Results: Strong Xtampza ER Start; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Depressed Opioid Sentiment Belies This Undervalued Growth Story; Assuming With Buy and $23 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
2019 Set to Be a Breakout Year for Xtampza ER; Affirm Buy, Adjust PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Additional Clarity With Full Year Financial Guidance; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
3Q Recap: Amended Terms on Nucynta Provides Added Flexibility; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
2Q Recap: New CEO; Positive Thesis Affirmed Following Thorough Model Refresh
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
4Q Review; Building an Emerging Leader in Opioid Pain Management; Raising PT to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Announced a deal with Depomed to license the rights to the opioid Nucynta - Buy
Provider: G.RESEARCH, LLC
Analyst: KEDRA K
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
3Q Recap: Payors Increasingly Turn to Xtampza ER, as Shares Approach 52-Week High; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Dare to Believe: FDA Approval of Expanded Claims to Accelerate Move to Xtampza; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E